Vildagliptin Efficacy in Combination with MetfoRmIn for EarlY Treatment of Type 2 Diabetes Mellitus (VERIFY)

被引：0
|
作者：
Sheu, Wayne Huey-Herng [1 ]
Prato, Stefano D. [2 ]
Foley, James [3 ]
Kothny, Wolfgang [4 ]
Kozlovski, Plamen [4 ]
Paldanius, Paeivi [4 ]
Stumvoll, Michael [5 ]
Matthews, David R. [6 ]
机构：
[1] Taichung Vet Gen Hosp, Dept Internal Med, Taichung, Taiwan
[2] Univ Pisa, Dept Endocrinol & Metab, Sect Metab Dis, Pisa, Italy
[3] Novartis Pharmaceut, E Hanover, NJ USA
[4] Novartis Pharma AG, Basel, Switzerland
[5] Univ Leipzig, Dept Med, D-04109 Leipzig, Germany
[6] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2014年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
482
引用
收藏
页码：254 / 255
页数：2
相关论文
共 50 条
  • [21] Efficacy, Safety and Treatment Satisfaction of Glimepiride vs Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus
    Kumar, Subodh
    Pathak, Anuj Kumar
    Saikia, Dibyajyoti
    Kumar, Amish
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2015, 9 (12) : FC07 - FC10
  • [22] Urinary metabolomic profiling in mice with diet-induced obesity and type 2 diabetes mellitus after treatment with metformin, vildagliptin and their combination
    Pelantova, Helena
    Buganova, Martina
    Holubova, Martina
    Sediva, Blanka
    Zemenova, Jana
    Sykora, David
    Kavalkova, Petra
    Haluzik, Martin
    Zelezna, Blanka
    Maletinska, Lenka
    Kunes, Jaroslav
    Kuzma, Marek
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2016, 431 (0C) : 88 - 100
  • [23] Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus
    Gonzalez-Ortiz, Manuel
    Guerrero-Romero, Jesus F.
    Violante-Ortiz, Rafael
    Wacher-Rodarte, Niels
    Martinez-Abundis, Esperanza
    Aguilar-Salinas, Carlos
    Islas-Andrade, Sergio
    Arechavaleta-Granell, Rosario
    Gonzalez-Canudas, Jorge
    Rodriguez-Moran, Martha
    Zavala-Suarez, Etelvina
    Ramos-Zavala, Maria G.
    Metha, Roopa
    Revilla-Monsalve, Cristina
    Beltran-Jaramillo, Teresita J.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2009, 23 (06) : 376 - 379
  • [24] Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin-metformin combination in newly diagnosed Type 2 diabetes
    Matthews, D. R.
    Paldanius, P. M.
    Proot, P.
    Foley, J. E.
    Stumvoll, M.
    Del Prato, S.
    DIABETIC MEDICINE, 2019, 36 (04) : 505 - 513
  • [25] Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
    Scheen, Andre J.
    Charpentier, Guillaume
    Ostgren, Carl Johan
    Hellqvist, Asa
    Gause-Nilsson, Ingrid
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2010, 26 (07) : 540 - 549
  • [26] The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus
    Kim, Gyuri
    Oh, Sewon
    Jin, Sang-Man
    Hur, Kyu Yeon
    Kim, Jae Hyeon
    Lee, Moon-Kyu
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (12) : 1179 - 1186
  • [27] Combination of glibenclamide-metformin HCl for the treatment of type 2 diabetes mellitus
    Lamos, Elizabeth Mary
    Stein, Stephanie Aleskow
    Davis, Stephen N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (17) : 2545 - 2554
  • [28] Efficacy and Safety of Gosogliptin as Monotherapy and in Combination with Metformin in Patients with Type 2 Diabetes Mellitus
    Trakhtenberg, Julia
    Vostokova, Natalia
    Karavaeva, Oksana
    Kreminskaya, Vera
    Ametov, Alexander
    DIABETES, 2015, 64 : A329 - A330
  • [29] Efficacy of insulin-metformin combination therapy in patients with type 2 diabetes mellitus
    Jaber, LA
    Slaughter, RL
    DIABETES, 1998, 47 : A88 - A88
  • [30] Vildagliptin: a new oral treatment for type 2 diabetes mellitus
    Mathieu, Chantal
    Degrande, Evy
    VASCULAR HEALTH AND RISK MANAGEMENT, 2008, 4 (06) : 1349 - 1360
12345